WO2012095543A1 - Nanocápsulas con cubierta polimérica - Google Patents
Nanocápsulas con cubierta polimérica Download PDFInfo
- Publication number
- WO2012095543A1 WO2012095543A1 PCT/ES2012/000008 ES2012000008W WO2012095543A1 WO 2012095543 A1 WO2012095543 A1 WO 2012095543A1 ES 2012000008 W ES2012000008 W ES 2012000008W WO 2012095543 A1 WO2012095543 A1 WO 2012095543A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- oil
- nanocapsules
- pga
- peg
- polyglutamic
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5192—Processes
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
- A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/70—Nanostructure
- Y10S977/773—Nanoparticle, i.e. structure having three dimensions of 100 nm or less
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/902—Specified use of nanostructure
- Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
- Y10S977/906—Drug delivery
Definitions
- the present invention relates to a system for the administration of active ingredients comprising nanocapsules of nanometric size, as well as to pharmaceutical compositions comprising them and processes for their preparation.
- Polyglutamic acid is a hydrophilic and biodegradable polymer consisting of glutamic acid units with a negative charge. Due to biological properties such as its non-toxicity, its non-immunogenicity and its biocompatibility, this polymer has become considered an important biomaterial for the development of new formulations for drug release (Buescher & Margaritis, Crit RevBiotech 2007).
- polyglutamic acid is widely reported for the formation of drug-polymer complexes of interest in the treatment of cancer, some formulations being found in advanced stages in their development.
- Xyotax a formulation consisting of conjugates between poly-L-glutamic acid and paclitaxel cytostatic agent, which is currently in phase 3 of clinical experimentation.
- This polymer has also been used in the design of formulations for the administration of other antitumor agents such as doxorubicin (Shih et al., 2004).
- nanoparticles Another type of release system developed from polyglutamic acid is nanoparticles, as described in US 2005238678 and US 6326511.
- polyglutamic acid has also been conjugated with polyethylene glycol (PEG) in order to achieve surface modifications of nanometric systems, trying to provide greater stability to colloidal systems.
- PEG polyethylene glycol
- Said modification with PEG also manages to minimize the recognition by proteins and cells of the endothelial reticulum system towards nanosystems, thus increasing their circulation time.
- Hyaluronic acid is a polymer of natural origin. More specifically, it is a glycosaminoglycan present in the extracellular matrix of connective tissues such as subcutaneous and cartilaginous; It is also found in the vitreous body of the eyeball and synovial fluid of the joint cavities. It is a polymer capable of interacting with the endogenous CD44 and RHAMM receptors that are located at the level of the cell surface in virtually all body cells, with the exception of red blood cells. The interaction of hyaluronic acid with these receptors allows the regulation of certain physiological processes such as mobility and cell proliferation.
- hyaluronic acid is used in therapeutics, as it exerts an important role in processes such as embryonic morphogenesis and development, cancer and inflammation.
- hyaluronic acid is used to promote epithelial healing. Proof of this biological activity are numerous works in which hyaluronic acid is included as an active biomolecule, mentioning those described by Sand et al. (Acta Ophthalmol. 67, 1989, 181-183), where hyaluronic acid is applied in the treatment of keratoconjunctivitis sicca, that of Nishida et al. (Exp. Eye Res.
- hyaluronic acid has also been the subject of numerous studies in which it is proposed to be used as a biomaterial-excipient used in the development of drug delivery systems. His interest in this line is due to the fact that it is a biodegradable, biocompatible, non-immunogenic, mucoadhesive polymer with selective affinity for receptors such as CD44.
- the background focused on obtaining nanometric formulations using hyaluronic acid as a biomaterial-excipient the following can be mentioned, among many others:
- Patent application US 2003/0166602 Al which discloses the elaboration of different formulations with a lipid modified with hyaluronic acid and that can house active ingredients with anticancer activity or other therapeutic or diagnostic agents.
- Patent application WO 2004/112758 Al which describes the preparation in aqueous medium of nanoparticles containing hyaluronic acid and which are formed by ionic interaction between it, other complementary charge polymers and in the presence of an ionic type crosslinker.
- L-asparagine is described in the literature as an essential amino acid for the growth and development of all types of cells, since it is directly involved in the synthesis of proteins and DNA and the main source of this amino acid is in the diet .
- L-asparagine is currently one of the most and best used strategies for the treatment of cancer, a formulation that includes the enzyme necessary for its degradation being commercialized.
- This formulation is called Oncaspar ® or Elspar ® , the enzyme responsible for this degradation being L-asparaginase.
- Cancer cells in advanced stages of metastasis, especially in leukemia have a high affinity towards asparagine due to a high surface recognition, due to their rapid reproduction. Cancer cells cannot effectively meet their basic needs of this amino acid, which in many cases results in the migration of these cells in search of higher concentrations of this amino acid towards the tumor periphery. Such recognition and need has recently been used as an alternative for the treatment of many cancers in stages of metastasis.
- nanometric systems such as polymer micelles or liposomes coated with asparagine-based polymer derivatives.
- nanocapsular system easily obtainable by different experimental procedures, wherein the nanocapsules comprise a polymer, an oil and a cationic surfactant.
- Such nanocapsule systems allow an effective association of lipophilic as well as hydrophilic active ingredients.
- the reduced size of these nanocapsules (diameter less than 1 ⁇ ) allows their passage through biological barriers and that are internalized by the cells.
- the presence of a polymeric cover in addition to conferring greater stability to the nanocapsules, provides different beneficial characteristics depending on each type of cover in particular.
- the invention is directed to a system for the administration of active ingredients comprising nanocapsules comprising an oil, a cationic surfactant, a polymer selected from the group consisting of polyglutamic acid (PGA), polyglutamic acid-polyethylene glycol (PGA-PEG), hyaluronic acid (HA) and polyasparagine (PAsn) or a combination thereof, and optionally an active ingredient,
- PGA polyglutamic acid
- PGA-PEG polyglutamic acid-polyethylene glycol
- HA hyaluronic acid
- PAsn polyasparagine
- nanocapsule system includes polyglutamic acid or polyglutamic acid-polyethylene glycol (PGA-PEG), then the active ingredient is not a didemnin or a tamandarin.
- PGA-PEG polyglutamic acid-polyethylene glycol
- nanocapsules of the invention may also optionally comprise other components such as a water soluble surfactant, an oil soluble surfactant or both.
- the invention in another aspect, relates to a pharmaceutical composition comprising the system defined above.
- the invention relates to the use of said system in the preparation of a medicament.
- said use is related to cancer treatment.
- the invention is directed to a process for obtaining the system defined above (referred to in the examples as a one-stage solvent diffusion process), comprising: a) preparing an aqueous solution comprising a polymer selected from the group consisting of polyglutamic acid (PGA), polyglutamic acid-polyethylene glycol (PGA-PEG), hyaluronic acid (HA) and polyasparagine (PAsn) or a combination thereof, and optionally a water soluble surfactant;
- PGA polyglutamic acid
- PGA-PEG polyglutamic acid-polyethylene glycol
- HA hyaluronic acid
- PAsn polyasparagine
- encapsulation of a lipophilic (hydrophobic) or amphiphilic active ingredient is carried out by adding it to step b).
- the active ingredients of hydrophilic nature can be added in step a) of the process or in a stage after step d) by an incubation process.
- the invention is directed to a process for obtaining the systems defined above, which comprises coating a nanoemulsion, consisting of at least one oil, a cationic surfactant, optionally an oil soluble surfactant, and an aqueous phase which optionally it comprises a water-soluble surfactant, with a polymer selected from the group consisting of polyglutamic acid (PGA), polyglutamic acid-polyethylene glycol (PGA-PEG), hyaluronic acid (HA) and polyasparagine (PAsn) or a combination thereof.
- PGA polyglutamic acid
- PGA-PEG polyglutamic acid-polyethylene glycol
- HA hyaluronic acid
- PAsn polyasparagine
- the above procedure further comprises adding an active ingredient.
- the polymer is polyglutamic acid or polyglutamic acid-polyethylene glycol (PGA-PEG)
- the active ingredient is not a didemnin or a tamandarin.
- said active ingredient in case the active ingredient has a lipophilic character, said active ingredient is added in the nanoemulsion formation process, preferably dissolved in ethanol.
- Figure 1 Evolution of particle size and polydispersion of nanocapsules of polyglutamic (1.a) and polyglutamic-polyethylene glycol (l.b) at 37 ° C for a period of 48 h.
- Figure 2 Particle size of nanocapsules of polyglutamic-polyethylene glycol (2.a) and polyglutamic (2.b), after being lyophilized at different concentrations (0.025-1% w / v) with the trehalose cryoprotectant (5 and 10% p / v).
- Figure 3 TEM images of hyaluronic acid nanocapsules prepared with the cationic surfactant benzalkonium chloride.
- DCX Docetaxel release profile obtained from hyaluronic acid nanocapsules prepared with the cationic surfactants benzalkonium chloride (BKC) and hexadecyltrimethylammonium bromide (CTAB).
- BKC benzalkonium chloride
- CTAB hexadecyltrimethylammonium bromide
- Figure 5 Evolution of the particle size of hyaluronic acid nanocapsules prepared with the cationic surfactant benzalkonium chloride (5.a) and hexadecyltrimethylammonium bromide (5.b) in storage at 4 ° C and 37 ° C, over a period 3 months
- Figure 6 Particle size of hyaluronic acid nanocapsules prepared with the cationic surfactant benzalkonium chloride, after being lyophilized at different concentrations (0.25-1% w / v) with the trehalose cryoprotectant (5 and 10% w / v).
- NCs HA white hyaluronic acid nanocapsules
- DCX docetaxel
- hyaluronic acid nanocapsules containing docetaxel for different concentrations of the antitumor.
- the cationic surfactant used in the preparation of the nanocapsules was hexadecyltrimethylammonium bromide.
- Figure 8 TEM images of polyasparagine nanocapsules made with the cationic surfactant benzalkonium chloride (8.a) or with hexadecyltrimethylammonium bromide (8.b).
- Figure 9 Docetaxel release profile (DCX) obtained from polyasparagine nanocapsules prepared with the cationic surfactant hexadecyltrimethylammonium bromide.
- Figure 10 Evolution of the particle size and zeta potential of polyasparagine nanocapsules prepared with the cationic surfactant of hexadecyltrimethylammonium bromide during storage at 4 ° C (10.a) and 37 ° C (10b) and of the same systems prepared with the cationic surfactant benzalkonium chloride during storage at 4 ° C (10 ° C) and 37 ° C (10 ° C).
- Figure 11 Viability of the NCI-H460 cancer cell line after 2 (11.a) and 48 (ll.b) hours of contact with white polyasparagine nanocapsules (PAsn NCs), docetaxel (DCX) in solution, and with nanocapsules of polyasparagine containing docetaxel, for different concentrations of the antitumor.
- the cationic surfactant used in preparation of the nanocapsules was hexadecyltrimethylammonium bromide.
- Figure 12 Fluorescence concentration expressed in photons / sec / cm / sr in different organs and tissues after administration of 100 nm polyglutamic-polyethylene glycol nanocapsules, after different time periods: (a) 6 hours, (b) 24 hours, (c) 48 hours; ( ⁇ administration subcutaneously, GHD administration intravenously).
- Figure 13 Fluorescence concentration expressed in photons / sec / cm / sr in different organs and tissues after administration of 200 nm polyglutamic-polyethylene glycol nanocapsules, after different time periods: (a) 6 hours, (b) 24 hours, (c) 48 hours; (administration subcutaneously, HHD administration intravenously).
- Figure 14 Kinetics of plasma elimination of fluorescence associated with the nanocapsules of PAsn (A), PGA ( ⁇ ) and PGA-PEG ( ⁇ ) after administration via the I.V. in Swiss mice.
- the percentage of the injected dose (concentration of DiD in mg / kg of the total weight of the animal at each time in relation to the concentration at zero time) is expressed as a function of time.
- the nanoemulsion ( ⁇ ) was used as a control.
- Figure 15 (a) Evolution of tumor size over time after administration of the nanocapsules of PAsn (A), PGA-PEG ( ⁇ ), Taxotere ® (- -X- -) and saline (X ) in mice (subcutaneous tumor model of glioma U87MG); (b) Increase in tumor volume, relative to the initial volume, that mice present after 18 and 21 days, after the injection of the different formulations. As controls were used the formulation Taxotere ® and physiological saline. Statistical analysis shows significant differences in tumor size on day 18 and day 21 in animals treated with nanocapsule formulations and Taxotere ® compared to the control (* P ⁇ 0.05 ** P ⁇ 0.01— F test YEAR GOES).
- Figure 16 Kaplan-Meier survival curves of animals treated with the different nanocapsule formulations loaded with docetaxel (PAsn nanocapsules ( ⁇ ), PGA-PEG ( ⁇ ), Taxotere ® ( ⁇ ) and saline (+) , compared to those obtained after the administration of Taxotere ® and saline control
- PAsn nanocapsules ⁇
- PGA-PEG ⁇
- Taxotere ® ⁇
- saline (+) saline
- the present invention is directed to the design and development of nanocapsules for the administration of active ingredients, wherein the nanocapsules of the system have a diameter of less than 1 ⁇ and are characterized by comprising (a) a shell of a polymer selected from the group consisting of polyglutamic acid, polyglutamic acid-polyethylene glycol, hyaluronic acid, polyasparagine or a combination thereof and (b) a core which in turn comprises an oil and a cationic surfactant.
- the nanocapsules of the invention also preferably comprise at least one active ingredient, with the proviso that when the polymer is polyglutamic acid or polyglutamic acid-polyethylene glycol (PGA-PEG), then the active ingredient is not a didemnin or a tamandarin.
- PGA-PEG polyglutamic acid-polyethylene glycol
- Nanocapsules nature and size
- nanocapsule systems with respect to emulsion systems is the presence of a polymer coating the oily nuclei that can give them greater stability and protection against aggregation, a change in the release profile of the associated drug, a greater cellular internalization and a specific interaction with certain cell types.
- the nanocapsules Compared to other systems such as liposomes or nanoparticles, which are generally conditioned by a limited drug load, the nanocapsules have a greater possibility of loading, in particular lipophilic drugs, due to the presence of the oily core.
- Another of the great advantages of nanocapsules is the ability to combine drugs of different nature, being able to be a lipophilic drug encapsulated in the nucleus and a hydrophilic drug associated with the shell; likewise, the cover gives them stability, protection and specificity.
- the nanometric size of release systems is essential in order to prevent blockage of blood capillaries.
- the possibilities of the nanosystems to reach the tumor tissue are strictly related to their size and also by the hydrophilic nature of their surface.
- the nanocapsules of the systems of the present invention have an average diameter of less than 1 ⁇ , thus responding to the definition of nanosystem, a colloidal system constituted based on polymers with a size less than 1 ⁇ , that is, they have a size between 1 and 999 nm, preferably between 30 and 500 nm.
- the size of the nanocapsules is mainly influenced by the composition and the formation conditions and can be measured using standard procedures known to those skilled in the art and described, for example, in the experimental part below. The size of the same does not vary significantly when the ratio of the cover compound in the formulation is modified, obtaining in all cases nanometric size systems. It is also important to highlight the difference between the nanocapsule systems and the "complexes".
- “Complexes” means the nanostructure formed by the interaction of polyelectrolytes or by polyelectrolytes and surfactants of opposite charge.
- the nanocapsule systems of the present invention differ from polyglutamic-paclitaxel (US 2003170201) or hyaluronic acid (Kim et al. J. Gene Med. (2009) 1 1: 791) complexes because they are a nanocapsular transport system , reservoir type, whose nucleus can accommodate a significant number of molecules that have a greater or lesser affinity for lipids (encapsulation) and whose cover can incorporate hydrophilic molecules that have a certain affinity for it (adsorption). These characteristics allow maintaining the integrity and functionality of the nanostructure, as well as providing greater stability in the presence of biological fluids.
- PGA Polyglutamic acid
- PGA-PEG polyglutamic acid-polyethylene glycol
- polyglutamic acid and its conjugate with PEG constitute very interesting biomaterials in the design of active molecule release systems.
- PGA includes water-soluble salts of PGA, such as ammonium salt and metal salts of PGA, such as lithium salt, sodium salt, potassium salt, magnesium salt, etc.
- the PGA form is selected from poly-D-glutamic acid, poly-L-glutamic acid, poly-D, L-glutamic acid, poly-a-glutamic acid, poly-aD- glutamic, poly-aL-glutamic acid, poly-aD, L-glutamic acid, poly-y-glutamic acid, poly-yD-glutamic acid, poly-yL-glutamic acid, and poly-yD, L-glutamic acid, and their mixtures
- the preferred form of PGA is poly-L-glutamic acid, and even more preferred is the sodium salt of poly-L-glutamic acid.
- the preferred form of PGA is poly-a-glutamic acid, and even more preferred is the sodium salt of poly-a-glutamic acid.
- the nanocapsules of the invention can be formed from water-soluble derivatives of PGA or PGA-PEG, where PGA is substituted in one or more available positions, for example the amine and / or carboxylic acid groups, with one or More suitable groups.
- Suitable derivatives of PGA and PGA-PEG include poly (alkylglutamine) derivatives and PEG-poly (alkylglutamine) derivatives, such as poly (N- 2- (2'-hydroxyethoxy) ethyl-L-glutamine) (PEEG), PEG -PEEG, poly (N-3- (hydroxypropyl) -L-glutamine) (PHPG), PEG-PHPG, poly (N-2- (hydroxyethyl) -L-glutamine) (PHEG), PEG-PHEG, poly (and -benzyl-L-glutamate) (pBG), PEG-pBG, poly (y-trichlorethyl-L-glutamate) (pTCEG), PEG-pTCEG, poly (dimethylaminoethyl-L-glutamine) (pDMAEG), PEG- pDMAEG, poly (pyridinoethyl-L-glutamine) (pPyAEG), PEG
- a cover based on a pegylated polymer gives nanocapsules greater stability in plasma and an increase in residence time in the body facilitating the arrival at the therapeutic target.
- the surface modification of the nanostructures with PEG chains manages to reduce their capture by the mononuclear phagocytic system through what has been called the shield system ("stealth system”) or long circulation time (“long circulation” systems ”) (Park JH et al, 2008). Thanks to their prolonged presence in the bloodstream, it was observed that these systems had a greater possibility of access to the target organs.
- This modification was of interest for the transport and orientation of cytostatic drugs, whose target tissue usually presents hypervascularization and increased permeability of blood vessels.
- Polyethylene glycol in its most common form, is a polymer of formula
- Xi is hydrogen or a hydroxyl radical protecting group that blocks OH function for subsequent reactions.
- Hydroxyl radical protecting groups are widely known in the art; Representative protecting groups (including already the oxygen to be protected) are for example silyl ethers such as trimethylsilyl ether, triethylsilyl ether, tert-butyldimethylsilyl ether, tert-butyldiphenylsilyl ether, triisopropylsilyl ether, diethylsopropylsilyl ether, texyldimethylsilyl, diphenyl ether, diphenyl ether, diphenyl ether tert-butylmethylsilyl ether; alkyl ethers, such as methyl ether, tert-butyl ether, benzyl ether, of p-methoxybenzyl ether, 3,4-dimethoxybenzyl ether, trityl ether, allyl
- hydroxyl protecting groups can be found in reference books such as "Protective Groups in Organic Synthesit.” from Greene and Wuts, John Wiley & Sons, Inc., New York, 1999.
- the protecting group is an alkyl ether, preferably that is methyl ether.
- X 2 is a bridge group that allows anchoring to polyglutamic acid groups and groups of derivatives thereof.
- X ⁇ can also be a group that allows anchoring with other PGAs and derivatives thereof.
- the PEGs are linked to PGA and its derivatives through the amine and / or carboxylic acid groups of the latter.
- Pegylation of the polymers can be performed using any suitable method available in the art (such as described in Veronese et al. DDT, 2005, 10 (21), 1451-1458; Nishiyama et al. Cancer Research 2003, 63, 8977-8983; Cabrera et al. J. Control. Relay, 2005, 101, 223-232; US 2003/0170201).
- a suitable molecular weight of PGA in PGA and PGA-PEG polymers can be between about 1 kDa and about 100 kDa, preferably between about 5 kDa and about 80 kDa, more preferably between about 10 kDa and about 50 kDa , and even more preferably about 10 kDa, about 15 kDa, about 20 kDa, about 25 kDa, about 30 kDa, and about 35 kDa.
- a suitable molecular weight for PEG in PGA-PEG polymers and in water-soluble derivatives thereof can be between about 1 kDa and about 50 kDa, preferably between about 2 kDa and about 40 kDa, more preferably between about 3 kDa and about 30 kDa, and even more preferably about 4 kDa, about 5 kDa, about 6 kDa, about 7 kDa, about 8 kDa, about 10 kDa, about 15 kDa, about 20 kDa, about 21 kDa, about 22 kDa, about 23 kDa, about 24 kDa, approximately 25 kDa, and approximately 30 kDa.
- PGA-PEG polymers and water soluble derivatives thereof are available in a variety of degrees of pegylation and the appropriate degree of pegylation for a given use is readily determined by one skilled in the art. This degree of pegylation is defined as the percentage of PGA functional groups or functional groups of PGA derivatives that are functionalized with PEG.
- suitable degrees of pegylation in PGA-PEG polymers and in water-soluble derivatives thereof can be between about 0.1% and about 10%, preferably between about 0.2% and about 5%, more preferably between about 0.5% and about 2%, and even more preferably about 0.5%, about 0.6%, about 0.7%, about 0.8%, about 0.9%, about 1%, about 1.1%, about 1.2%, about 1.3%, about 1.4 %, about 1.5%, about 1.6%, about 1.7%, about 1.8%, about 1.9%, and about 2%.
- the proportion of PEG in the PGA-PEG polymers and water-soluble derivatives thereof can be between about 10% and 90% (w / w) with respect to the total weight of the polymer, preferably between about 15% and 80% , more preferably between about 20% and 70%, and even more preferably about 20%, about 22%, about 24%, about 26%, about 28%, about 30%, about 32%, about 34%, about 36% , about 38%, about 40%, about 42%, about 44%, about 46%, about 48%, about 50%, about 52%, about 54%, about 56%, about 58%, and about 60%.
- hyaluronic acid on the surface of the nanocapsules gives them the ability to adhere to mucous surfaces due to their known mucoadhesive property.
- they have a great potential to achieve an active vehiculization towards cells that show rapid growth and overexpression of the CD44 receptor, which allows them to form tissues; A clear example of this cellular behavior is evidenced in several types of cancer cells.
- HA includes water-soluble salts of HA as well as water-soluble derivatives of HA.
- the hyaluronic acid salt is selected from the group consisting of sodium, potassium, magnesium, calcium and zinc salt.
- the hyaluronic acid salt is sodium.
- the presence of the neutral polyamino acid polyamino acid on the surface gives the nanocapsule stability, a long life in the body, protection against mononuclear phagocytic system and specificity in its interaction with certain target cells.
- polyasparagine on the surface of the nanocapsules also provides greater specificity to cancer cells by the systems, because these cells have a greater need for asparagine to maintain their development. Cancer cells are unable to self-satisfy their needs for this amino acid, contrary to what happens with normal cells.
- PAsn includes the water soluble salts of PAsn as well as water soluble derivatives of PAsn.
- the nanocapsules comprise an oil and a cationic surfactant in the core.
- the oil can be volatile or non-volatile and in a particular embodiment, it is selected from natural, semi-synthetic and synthetic oils for pharmaceutical use or a combination thereof, such as animal, vegetable, hydrocarbon oils or silicone oils.
- Suitable oils include, but are not limited to, mineral oil, squalene oil, flavor oils, silicone oil, essential oils, water insoluble vitamins, isopropyl stearate, butyl stearate, octyl palmitate, cetyl palmitate, tridecyl behenate, diisopropyl adipate , dioctyl sebacate, mentyl anthranilate, cetyl octanoate, octyl salicylate, isopropyl myristate, neopentyl glycol dicarpath ketoles, Cerafilos®, decyl oleate, C 12- C 15 alkyl lactates, cetyl lactate, lauryl lactate, isostearyl neopentanoate, miristyl lactate, isoistyl lactate, isoistyl lactate, isoistyl lactate, isoistyl lactate, isoistyl lactate
- the oil is selected from peanut oil, cotton, olive, castor, soy, safflower, palm; Vitamin E, Isopropyl Myristate, Squalene, Miglyol®, Labrafil®, Labrafac®, Peceol® and Maisine® or mixtures thereof.
- the oil is Miglyol®.
- the term "cationic surfactant” refers to a component that has structures and / or functional groups that allow them to interact simultaneously with the lipophilic and hydrophilic part of the formulation being the latter interaction favored by the presence of a cationic functional group .
- the cationic surfactant is selected from highly cationizable primary, secondary and tertiary amines and quaternary amines.
- the cationic surfactant is selected from oxylamine, stearylamine, benzalkonium chloride, benzethonium chloride, cetylpyridinium chloride, cetylthyridinium bromide, dodecyltrimethylammonium bromide, trimethyltetradecylammonium bromide, hexadecyltrimethyl ammonium bromide (p-ammonium bromide). Tetronic®) or mixtures thereof.
- the cationic surfactant is benzalkonium chloride or hexadecyltrimethylammonium bromide.
- the nanocapsules according to the present invention may optionally contain an oil-soluble surfactant, a water-soluble surfactant or both, which sterically favor the stability of the system and which allow modulating the surface electric charge of the nanocapsules and providing stability to the system.
- oil soluble surfactant or
- water soluble surfactant refers to components that have structures and / or functional groups that allow them to interact simultaneously with the lipophilic and hydrophilic part of the formulation, the interaction being favored with respect to the lipophilic part in the case of soluble surfactants in oil or with respect to the hydrophilic part in the case of water soluble surfactants.
- suitable surfactants in the present invention include phospholipids such as lecithin, phosphatidylglycerol, phosphatidylserine, phosphatidylinositol, diphosphatidylglycerol, phosphatidic acid, phosphatidylethanolamine; cholesterol; glyceryl monostearate; polyoxyethylene polypropylene copolymers (poloxamers); polyethylene glycol; polypropylene glycol; cetyl alcohol; ketostearyl alcohol; stearyl alcohol; aryl alkyl polyether alcohols; sorbitan fatty acid esters
- Span® and Arlacel® polyoxyethylene fatty acid esters
- Myrj® polyoxyethylene fatty acid esters
- fatty acid esters of polyoxyethylene sorbitan polysorbates
- polyoxyethylene alkyl ethers polyoxyethylene alkyl ethers
- ethers of fatty alcohols such as Brij®
- the oil-soluble surfactant is a phospholipid selected from lecithin, phosphatidylglycerol, phosphatidylserine, phosphatidylinositol, diphosphatidylglycerol, phosphatidic acid, phosphatidylcholine and phosphatidylethanolamine, preferably lecithin.
- the water-soluble surfactant is a hydrophilic derivative of polyethylene ethylene, preferably poloxamer, or a polysorbate.
- polyethylene ethylene preferably poloxamer, or a polysorbate.
- polyxamer refers to a nonionic triblock copolymer. composed of a central hydrophobic polyoxypropylene chain linked to two hydrophilic polyoxyethylene chains.
- the poloxamer is 188.
- the nanocapsules of the invention also optionally comprise at least one active ingredient.
- active ingredient refers to any substance that is used in the treatment, cure, prevention or diagnosis of a disease or that is used to improve the physical and mental well-being of humans and animals.
- the active ingredient may be for example a drug, a vitamin, etc.
- the nanocapsule systems object of the present invention are suitable for incorporating active ingredients of lipophilic or hydrophilic nature.
- the active ingredient is docetaxel.
- the proportion of active ingredient incorporated will depend in each case on the active ingredient to be incorporated, the indication for which it is used and the administration efficiency.
- Nanocapsules comprising an oil, a cationic surfactant, a polymer selected from PGA and PGA-PEG and an active ingredient selected from a didemnin or a tamandarin are outside the present patent application and are the subject of European patent application EPl 1382003.9 with the title "Nanocapsules for use in pharmaceutical compositions", deposited the same day as the present application.
- Didemnins and tamandarins are cyclodepsypeptides that exhibit a wide variety of biological activities, such as antitumor, immunosuppressive and antiviral. Examples of such compounds (excluded from the present invention for PGA or PGA-PEG nanocapsules) fall within the following general formula:
- X is selected from O and NH
- Y is selected from CO and -COCH (CH 3 ) CO-;
- n and p are independently selected between 0 and 1, and q is selected between 0, 1 and 2;
- Ri, R 3 , R 5 , R 9 , Rn, and R 15 are independently selected from hydrogen, Ci-C substituted or unsubstituted alkyl, C 2 -C 6 substituted or unsubstituted alkenyl, and C 2 -C 6 substituted alkynyl or unsubstituted;
- R 2 is selected from hydrogen, COR a , COOR a , Ct-C substituted or unsubstituted alkyl, C 2 -C 6 substituted or unsubstituted alkenyl, and C 2 -C 6 substituted or unsubstituted alkynyl;
- R4, R 8 , Rio, R12, and RI ⁇ are independently selected from hydrogen and C ⁇ -C substituted or unsubstituted alkyl;
- R 7 and R 13 are independently selected from hydrogen, Cj-C 6 substituted or unsubstituted alkyl, C 2 -C 6 substituted or unsubstituted alkenyl, and C 2 -C 6 substituted or unsubstituted alkynyl;
- R 6 and Ri 4 are independently selected from hydrogen and Ci-C 6 substituted or unsubstituted alkyl; or R and R 7 and / or R 13 and R 14 , together with their corresponding N and C atoms to which they are attached, can form a substituted or unsubstituted heterocyclic group;
- Ra, Rb, and R c are independently selected from hydrogen, C-Cn substituted or unsubstituted alkyl, C 2 -C 12 substituted or unsubstituted alkenyl, and C 2 -C 12 substituted or unsubstituted alkynyl, substituted or unsubstituted aryl , and substituted or unsubstituted heterocyclic group; or a pharmaceutically acceptable salt, prodrug or stereoisomer thereof.
- the nanocapsules comprise polyglutamic acid or polyglutamic acid-polyethylene glycol (PGA-PEG), then the active ingredient is not aplidine.
- a particular process for obtaining the systems of the invention comprises: a) preparing an aqueous solution comprising a polymer selected from the group consisting of polyglutamic acid (PGA) , polyglutamic acid-polyethylene glycol (PGA-PEG), hyaluronic acid (HA) and polyasparagine (PAsn) or a combination thereof, and optionally a water soluble surfactant;
- PGA polyglutamic acid
- PGA-PEG polyglutamic acid-polyethylene glycol
- HA hyaluronic acid
- PAsn polyasparagine
- the addition of the organic solution c) can be carried out in aliquots of volumes of between 250 ⁇ and 500 ⁇ , at time intervals of between 15 and 25 seconds.
- the systems of the present invention can be prepared by an alternative method (referred to in the examples as a two-stage solvent diffusion process) comprising coating a cationic nanoemulsion with the coating polymer by an incubation process with an aqueous solution of the polymer.
- a two-stage solvent diffusion process comprising coating a cationic nanoemulsion with the coating polymer by an incubation process with an aqueous solution of the polymer.
- the formation of the nanoemulsion can be favored by ultrasound (called in the examples sonication procedure) or homogenization (called in the examples homogenization procedure).
- the incubation process comprises mixing the cationic nanoemulsion with an aqueous solution of the coating polymer.
- Said cationic nanoemulsion consists of at least one oil, a cationic surfactant and an aqueous phase.
- the aqueous phase may contain other surfactants, salts, and other auxiliary agents.
- the processes for preparing said nanoemulsion are known in the state of the art, and can comprise a diffusion, sonication or homogenization process (Prego et al. J. Nanosci. Nanotechnol. (2006) 6: 1; Tadros et al. Adv Colloid Interface Sci. (2004) 109: 303).
- a particular process for obtaining the cationic nanoemulsion (referred to in the examples as solvent diffusion process) comprises:
- step ii) adding the solution obtained in step i) over an aqueous phase that optionally contains a water-soluble surfactant and that is under stirring to form a cationic nanoemulsion; iii) optionally, evaporate all or part of the organic solvents to constant volume.
- Another particular process for obtaining the cationic nanoemulsion (referred to in the examples as sonication procedure) comprises:
- step ii) add the solution obtained in step i) over an aqueous phase that optionally contains a water-soluble surfactant and sonicate;
- homogenization procedure comprises:
- step ii) add the solution obtained in step i) over an aqueous phase that optionally contains a water soluble surfactant and homogenize; iii) dilute with water the emulsion obtained in phase ii) and homogenize;
- the active ingredient is lipophilic or amphiphilic
- said active ingredient is added to the organic solution of step b) or step i).
- said active ingredient is added to the solution of stage a) or stage ii).
- said hydrophilic active ingredient is added dissolved in an aqueous solution. It is also possible to incorporate the hydrophilic active ingredient by adsorption to the suspension of nanocapsules obtained in step d) or after the incubation process once the nanocapsules are formed.
- nanocapsules occurs when mixing volumes of the mentioned solutions containing the cationic nanoemulsion with solutions aqueous coating polymer in different proportions, varying the ratio of coating polymer.
- the proportion of PGA, PGA-PEG and HA is between 0.05 and 12% w / w (coating polymer weight / formulation weight, dry base).
- the aqueous coating polymer solution is composed of 0.1-25 mg / ml of said polymer.
- the proportion of PAsn is between 2.5 and 30% w / w (coating polymer weight / formulation weight, dry base).
- the aqueous solution of this coating polymer is composed of 1-60 mg / ml of said polymer.
- the solvent of the organic solution is preferably a mixture of polar solvents such as ethanol and acetone and may also include non-polar solvents such as dichloromethane.
- polar solvents such as ethanol and acetone
- non-polar solvents such as dichloromethane.
- the oil and the cationic surfactant are incorporated, and optionally the oil-soluble surfactant.
- the active ingredient is also incorporated.
- a particular example for obtaining the nanocapsule systems of the invention comprising PGA or PGA-PEG following the first procedure described above comprises:
- a particular example for obtaining the nanocapsule systems of the invention of PAsn following the first procedure described above comprises:
- a particular example for obtaining the nanocapsule systems of the invention of HA following the first procedure described above comprises:
- the process for preparing nanocapsule systems may include an additional lyophilization stage, in order to preserve them during storage so that they retain their initial characteristics.
- the lyophilization of the systems requires the addition of sugars that have a cryoprotective effect.
- sugars useful for carrying out lyophilization are, for example, trehalose, glucose, sucrose, mannitol, maltose, polyvinyl pyrrolidone (PVP).
- PVP polyvinyl pyrrolidone
- the present invention also relates to nanocapsule systems comprising a polyglutamic acid, polyglutamic polyethylene glycol, polyasparagine or hyaluronic acid shell in the form of lyophilisate.
- nanocapsule systems described herein have adequate stability both in suspension and in the form of lyophilisate.
- stability studies seem to indicate that after administration to organisms, human or animal, they do not undergo a rapid aggregation or destruction process, but predictably remain in nanocapsular form until reaching the target tissue or cell.
- nanocapsule systems of this invention have advantages compared to other drug delivery and / or delivery systems, due to their unique behavior in terms of:
- the system may include one or more active ingredients or adjuvant substances, hydrophilic or lipophilic, in proportions greater than that of nanoparticles, micelles, complexes, nanogels.
- the cover exerts a function on its release rate, allowing the active ingredient to be released in a controlled manner according to application and needs.
- the polymeric shell gives lipid cores great stability, which represents an advantage over other micro and nanoemulsion systems.
- the polymeric shell gives the lipid nuclei the possibility of interacting with mucous surfaces as well as with specific epithelia and cells.
- the invention in a particular embodiment relates to a pharmaceutical composition, comprising the above nanocapsule systems, and optionally one or more pharmaceutically acceptable excipients.
- the incorporation of active ingredients in the nanocapsules of the invention originates systems, whose characteristics in terms of their composition, properties and morphology, make them excellent candidates for the therapeutic area.
- the active ingredient to be incorporated in the systems of the invention will be that with suitable pharmacotherapeutic properties according to the therapeutic application to which the formulation is intended.
- the active ingredient is selected from peptides, proteins, lipid or lipophilic compounds, saccharide compounds, nucleic acid or nucleotide compounds such as oligonucleotides, polynucleotides or combinations of the aforementioned molecules.
- the lipophilic active ingredient is docetaxel.
- the active ingredient is selected from an oligonucleotide, interfering RNA, a DNA plasmid or a polynucleotide, more preferably the active ingredient is a DNA plasmid.
- the active ingredient is hydrophobic, amphiphilic or hydrophilic in nature.
- the active ingredients of hydrophobic or amphiphilic nature are preferably added in step b) of the nanocapsule preparation process of the invention.
- the active ingredients of hydrophilic nature are preferably added in step a) of the process or in a stage after d) by an incubation process.
- the invention also contemplates other embodiments such as adding in step b) a hydrophilic active ingredient dissolved in a small volume of aqueous phase.
- the active ingredients of hydrophilic nature can be associated with their surface by adsorption.
- the active ingredient is not a didemnin or a tamandarin.
- Said pharmaceutical compositions can be administered by different routes, such as through mucous membranes, topically or parenterally.
- the proportion of active ingredient incorporated in the systems can be up to about 50% by weight with respect to the total weight, dry basis, of the nanocapsule system components. However, the appropriate proportion will depend in each case on the active ingredient to be incorporated, the indication for which it is used and the administration efficiency.
- the proportion of lipophilic active ingredient can be up to about 10% by weight, preferably up to about 5%.
- the nanocapsule systems described in the present invention incorporate more than one active ingredient, which may be dissolved in the same solution or separately, depending on the nature of the molecules to be incorporated. , preventing any kind of interaction, whether chemical or physical, between them.
- the invention relates to the use of said system in the preparation of a medicament.
- said use is related to cancer treatment.
- PGA Poly-L-glutamic acid;
- the PGA salt used in the following examples was the sodium salt of molecular weight between 15,000 and 50,000 Da (SIGMA).
- PGA-PEG 16000 Da Poly-L-glutamic acid-polyethylene glycol acid; the PGA-PEG salt used in the following examples was the sodium salt of molecular weight of 16000 Da, in particular with a percentage of peguilation of 6% and a PEG chain size of 1000 Da (Alamanda Polymers USA).
- PGA-PEG 22000 Da Poly-L-glutamic-polyethylene glycol acid;
- the PGA-PEG salt used in the following examples was the sodium salt of molecular weight of 22,000 Da, in particular with a pegylation percentage of 93% and a PEG chain size of 20,000 Da (Alamanda Polymers USA).
- PGA-PEG 35000 Da Poly-L-glutamic-polyethylene glycol acid;
- the PGA-PEG salt used in the following examples was the sodium salt of 35,000 Da molecular weight, in particular with a 60% peguylation percentage and a PEG chain size of 20,000 Da (Alamanda Polymers USA).
- HA hyaluronic acid
- the HA salt used in the following examples was the sodium hyaluronate of molecular weight between 20,000 and 50,000 Da and 165,000 Da. (Imquiaroma, France).
- PAsn Poliasparagine
- the polyasparagine used preferably has a molecular weight of 5000 to 15000 Da, with approximately 5% of aspartic acid residues (SIGMA).
- BKC Benzalkonium Chloride (SIGMA).
- CTAB Hexadecyltrimethylammonium bromide (SIGMA).
- DCX Docetaxel (SIGMA).
- Nanoemulsion (NE) This term is used for simplicity in the examples to refer to nanosystems comprised of a lecithin, Miglyol® 812, a cationic surfactant (benzalkonium chloride or hexadecyltrimethylammonium bromide), optionally poloxamer 188 and whose only difference with Nanocapsules is the absence of a coating polymer on the surface of the systems.
- a lecithin Miglyol® 812
- a cationic surfactant benzalkonium chloride or hexadecyltrimethylammonium bromide
- poloxamer 188 optionally poloxamer 188
- NCs PGA nanocapsules
- NCs PGA-PEG nanocapsules
- Nanocapsules (NCs) of HA This term is used for simplicity in the examples and figures to refer to nanosystems whose nanocapsules include lecithin, Miglyol® 812, a cationic surfactant (benzalkonium chloride or hexadecyltrimethylammonium bromide), poloxamer 188 and HA .
- Nanocapsules (NCs) of PAsn This term is used for simplicity in the examples and figures to refer to nanosystems whose nanocapsules comprise polyaparagin, lecithin, Miglyol® 812, a cationic surfactant (benzalkonium chloride or hexadecyltrimethylammonium bromide) and optionally poloxamide. 188.
- Nanocapsules consisting of an oily core coated with PGA or PGA-PEG were prepared according to the solvent diffusion process in two stages:
- step i) the solution obtained in step i) is added on 20 ml of a 0.25% w / v aqueous solution of poloxamer 188 under magnetic stirring being maintained for 10 minutes, in this way the cationic nanoemulsion is spontaneously obtained;
- the cationic nanoemulsion obtained in step iii) was coated by an incubation process with an aqueous solution (1.5 ml) composed of 0.1 to 25 mg / ml of polyglutamic or polyglutamic-polyethylene glycol of different molecular weight, in a ratio 4: 1.5 v / v (nanoemulsion: polymer solution), the coating is produced immediately, regardless of temperature.
- Tables 1, 2, 3, 4 show the values obtained from the parameters cited as a function of the amount of polyglutamic and polyglutamic-polyethylene glycol of different molecular weights in step iv).
- NC PGA-PEG 22000Da 100 227 ⁇ 6 0.1 -6 ⁇ 1
- Nanocapsules consisting of an oily core coated with polyglutamic or polyglutamic-polyethylene glycol were prepared according to the solvent diffusion process in one step:
- an aqueous solution (20 ml) was prepared in which 0.5 to 25 mg / ml of polyglutamic or polyglutamic-polyethylene glycol is dissolved which is 0.25% w / v of poloxamer 188;
- Tables 5, 6, 7 and 8 show the values obtained from the parameters mentioned in the determination of the amount of polyglutamic or polyglutamic-polyethylene glycol in the aqueous solution of step a).
- NC PGA-PEG 35000Da 100 174 ⁇ 4 0.1 -42 ⁇ 3
- Nanocapsules consisting of an oily core coated with polyglutamic or polyglutamic-polyethylene glycol were prepared according to the sonication procedure:
- step i) the solution obtained in step i) was added over 2 ml of water containing poloxamer 188 at 0.25% w / v, sonic for 1 minute;
- step iv) the cationic nanoemulsion obtained in step iv) was coated by a
- aqueous solution 1.5 ml
- aqueous solution composed of 0.1 to 25 mg / ml of polyglutamic or polyglutamic-polyethylene glycol, in a 4: 1, 5 ratio (nanoemulsion: polyglutamic or polyglutamic-polyethylene glycol solution)
- the coating is produced immediately, regardless of the temperature.
- Tables 9, 10, 1 1 and 12 show the values obtained from the parameters cited according to the amount of polyglutamic or polyglutamic-polyethylene glycol in step v).
- NC PGA-PEG 22000Da 100 195 ⁇ 5 0.1 -6 ⁇ 1
- NC PGA-PEG 35000Da 100 203 ⁇ 10 0, 1 -45 ⁇ 1
- Nanocapsules consisting of an oily core coated with polyglutamic or polyglutamic-polyethylene glycol were prepared according to the homogenization procedure:
- an oil phase consisting of a solution of lecithin (30 mg) and the cationic surfactant of benzalkonium chloride (7 mg) in dichloromethane (1 ml) was prepared to which 125 ⁇ of Miglyol® 812 is added; ii) the solution obtained in step i) was added over 2 ml of water containing 0.25% w / v poloxamer 188 and homogenized at 16,000 rpm for 5 minutes and then at 19,000 rpm for another 5 minutes;
- the emulsion obtained was diluted with water (1: 10 dilution) and homogenized for 3 minutes at 22,000 rpm;
- step iv) the nanoemulsion obtained in step iv) was coated by an incubation process with an aqueous solution (1.5 ml) composed of 0.1 to 25 mg / ml of polyglutamic or polyglutamic-sodium polyethylene glycol, in a proportion 4 : 1,5 (nanoemulsiómdisolution of polyglutamic or polyglutamic-polyethylene glycol), producing the coating immediately, regardless of temperature.
- Tables 13, 14, 15 and 16 show the values obtained from the parameters mentioned according to the amount of polyglutamic or polyglutamic-polyethylene glycol in step v).
- NC PGA 10 187 ⁇ 7 0.2 -65 ⁇ 5
- NC PGA-PEG 22000Da 100 201 ⁇ 2 0.1 -8 ⁇ 1
- NC PGA-PEG 35000Da 100 189 ⁇ 14 0.2 -42 ⁇ 2 NC PGA-PEG 35000Da 50 186 ⁇ 7 0.2 -33 ⁇ 7
- Nanocapsules of polyglutamic or polyglutamic-polyethylene glycol of 35000 Da were prepared in the form of sodium salt, an oily core composed of lecithin, Miglyol® 812 and the cationic surfactant benzalkonium chloride (7 mg) and poloxamer 188.
- the manufacturing process corresponds to the procedure previously described in Example 1.1., With a modification, since a small aliquot of a stock solution of the active ingredient in ethanol (1-100 mg / ml) is incorporated into the oil phase.
- the system is then rotated to a constant volume and incubated with a solution of polyglutamic or polyglutamic-polyethylene glycol of 35000 Da forming the nanocapsules encapsulating docetaxel with weight ratios of docetaxel or nanocapsules of polyglutamic or polyglutamic-polyethylene glycol up to 35000 Da 4 %.
- the parameters mean particle diameter, polydispersion index and zeta potential were also measured (Table 17).
- Nanocapsules of polyglutamic or polyglutamic-polyethylene glycol of 35000 Da were prepared in the form of sodium salt, an oily core composed of lecithin, Miglyol® 812, and benzalkonium chloride (7 mg) and poloxamer 188 according to the procedure previously described. Particle size measurements were made during a relevant time, in order to obtain information about the evolution of the system over time. The effect of storage temperature (37 ° C) on the stability of the nanocapsules was also evaluated. The results presented in figures la and Ib show the limited variability in the size of the polycalutamic or polyglutamic-polyethylene glycol nanocapsules of 35000 Da at 5.8% w / w during storage.
- Nanocapsules of polyglutamic or polyglutamic-polyethylene glycol in the form of sodium salt, an oily core composed of lecithin, Miglyol® 812 and the cationic surfactant of benzalkonium chloride (7 mg) and poloxamer 188 were prepared, according to the procedure previously described.
- the effect of the trehalose cryoprotectant agent during the lyophilization process of the polyglutamic or polyglutamic-polyethylene glycol nanocapsules and the subsequent recovery of the particle size after resuspension was tested by testing two concentrations of trehalose, 5 and 10% w / v.
- Nanocapsules consisting of an oily core coated with HA were prepared according to the two-stage solvent diffusion process:
- an oil phase consisting of an ethanol / acetone solution (0.5: 9 ml) of lecithin (30 mg) and the cationic surfactants of benzalkonium chloride (4 mg) or hexadecyltrimethylammonium bromide (1.8 mg) was prepared, to which 125 ⁇ of Miglyol® 812 is added.
- the solution obtained in step i) is added over 20 ml of a 0.25% w / v aqueous solution of poloxamer 188 under magnetic stirring being kept for 10 minutes , in this way the cationic nanoemulsion is spontaneously obtained;
- the organic solvents were evaporated to constant volume;
- step iii) the cationic nanoemulsion obtained in step iii) was coated by an incubation process with an aqueous solution (1.5 ml) composed of 0.1 to 25 mg of sodium hyaluronate, in a 4: 1, 5 ratio ( nanoemulsion: solution of HA), the coating is produced immediately, regardless of temperature.
- Tables 18 and 19 show the values obtained from the parameters cited as a function of the amount of HA of 20000-50000 Da in step iv) and using benzalkonium chloride or hexadecyltrimethylammonium bromide, respectively.
- Table 20 shows the values obtained from the parameters cited according to the amount of HA of 160000 Da in step iv) and using benzalkonium chloride.
- Nanocapsules consisting of an oleosorecoated HA core were prepared according to the one-stage solvent diffusion procedure:
- an aqueous solution of sodium hyaluronate (20 ml) was prepared in which 0.5 to 25 mg of HA of 20000-50000 Da is dissolved and is 0.25% w / v poloxamer 188;
- Nanocapsules consisting of an oily core coated with HA were prepared according to the sonication procedure:
- an oil phase consisting of a solution of lecithin (30 mg) and the cationic surfactant of benzalkonium chloride (4 mg) in dichloromethane (1 ml) was prepared to which 125 ⁇ of Miglyol® 812 is added; ii) the solution obtained in step i) was added over 2 ml of water containing poloxamer 188 at 0.25% w / v, sonic for 1 minute; iii) the emulsion obtained was diluted with water (1: 10 dilution);
- step iv) the cationic nanoemulsion obtained in step iv) was coated by an incubation process with an aqueous solution (ml - 5 ml) composed of 0.5 to 25 mg of sodium hyaluronate, in a 4: 1.5 v ratio / v (nanoemulsion: solution of HA), producing the coating immediately, regardless of temperature.
- Table 23 shows the values obtained from the parameters cited as a function of the amount of HA in stage v).
- Nanocapsules consisting of an HA-coated oily core were prepared according to the homogenization procedure:
- an oil phase consisting of a solution of lecithin (30 mg) and the cationic surfactant of benzalkonium chloride (4 mg) in dichloromethane (1 ml) was prepared to which 125 ⁇ of Miglyol® 812 is added; ii) the solution obtained in step i) was added over 2 ml of water containing 0.25% w / v poloxamer 188 and homogenized at 16,000 rpm for 5 minutes and then at 19,000 rpm for another 5 minutes;
- the emulsion obtained was diluted with water (1: 10 dilution) and homogenized for 3 minutes at 22,000 rpm;
- step iv) the nanoemulsion obtained in step iv) was coated by an incubation process with an aqueous solution (1.5 ml) composed of 0.5 to 25 mg of sodium hyaluronate, in a 4: 1.5 ratio (nanoemulsion: solution of HA), producing the coating immediately, regardless of temperature.
- Table 24 shows the values obtained from the parameters cited as a function of the amount of HA in step v).
- HA nanocapsules in the form of sodium salt, an oily core composed of lecithin, Miglyol® 812 and the cationic surfactants of benzalkonium chloride (4 mg) or hexadecyltrimethylammonium bromide (1.8 mg) and poloxamer 188 were prepared.
- the manufacturing process corresponds to the procedure previously described in Example 5.1, with a modification, since a small aliquot of a stock solution of the active ingredient in ethanol (1-100 mg / ml) is incorporated into the oil phase.
- the system is rotated to a constant volume and incubated with a solution of HA forming the nanocapsules of HA encapsulating docetaxel with weight ratios of docetaxel / nanocapsules of HA of up to 4%.
- the encapsulation efficiency was determined (by evaluating the free drug by high performance liquid chromatography, with obtaining an encapsulation efficiency of -65%.
- the parameters mean particle diameter, polydispersion index and zeta potential were also measured (Table 25). TABLE 25
- HA nanocapsules were prepared by encapsulating the lipophilic docetaxel drug following the procedure described in example 6. The nanocapsules were diluted in water and incubated in this medium under horizontal agitation (100 rpm) at 37 ° C. At various times samples were taken from the incubation media and the nanocapsules were isolated in suspension by ultracentrifugation. Finally, the fraction of drug released was assessed by quantifying the amount of free drug in the infringing liquid which was checked against that fraction of the drug that remained bound to the nanocapsules. The quantification of docetaxel was performed as described in example 6. The drug assignment profile of the HA nanocapsules is shown in Figure 4. Example 8
- HA nanocapsules in the form of sodium salt, an oily core composed of lecithin, Miglyol® 812 and benzalkonium chloride (4 mg) or hexadecyltrimethylammonium (5.4 mg) and poloxamer 188 were prepared according to the procedure previously described. Particle size measurements were made during a relevant time, in order to obtain information about the evolution of the system over time. The effect of storage temperature (4 and 37 ° C) on the stability of the nanocapsules was also evaluated.
- HA nanocapsules in the form of sodium salt, an oily core composed of lecithin, Miglyol® 812 and the cationic surfactant of benzalkonium chloride (4 mg) and poloxamer 188 were prepared, according to the procedure previously described.
- the effect of the trehalose cryoprotective agent during the lyophilization process of HA nanocapsules and in the subsequent recovery of particle size after resuspension was tested by testing two concentrations of trehalose, 5 and 10% w / v.
- the influence of the concentration of nanocapsules (0.25, 0.5 and 1% w / v) on the suspension to be lyophilized was evaluated.
- the results in Figure 6 show the particle size of lyophilized HA nanocapsules after resuspension.
- HA nanocapsules were prepared using hexadecyltrimethylammonium bromide (1.8 mg) according to procedure described in example 6.
- the results shown in Figure 7 show the greater capacity to inhibit the proliferation of the nanocapsules encapsulating docetaxel compared to the free molecule when the systems come into contact for 2 and 48 hours with the cells. carcinogenic On the other hand, the safety of systems without docetaxel can be appreciated.
- docetaxel solution had IC50 values of 105 and 36 nM when in contact with the cells for 2 and 48 respectively; while HA nanocapsule formulations encapsulating docetaxel showed values of ⁇ 29 and -13 nM at the same incubation times, resulting in nanoencapsulation of docetaxel 3.6 and 2.8 times more effective inhibition of cell proliferation.
- Nanocapsules consisting of an oily core coated with PAsn were prepared according to the two-stage solvent diffusion procedure:
- an oil phase consisting of an ethanol / acetone solution (0.5: 9 ml) of lecithin (30 mg) and the cationic surfactant benzalkonium chloride (4 mg) or hexadecyltrimethylammonium bromide (1.8 mg) was prepared, to which 0.125 ml of Miglyol® 812 is added.
- step i) the solution obtained in step i) is added to 10 ml of water under magnetic stirring, maintaining for 10 minutes, in this way the cationic nanoemulsion is spontaneously obtained;
- step iii) the cationic nanoemulsion obtained in step iii) was coated by an incubation process with an aqueous solution (1 ml) composed of different amounts of PAsn, in a 3.7: 1 ratio, immediately producing the coating, of temperature independent way.
- Tables 26 and 27 show the values obtained from the parameters cited according to the amount of PAsn in step iv) and using benzalkonium chloride (4 mg) or hexadecyltrimethylammonium bromide (1.4 mg), respectively.
- Nanocapsules consisting of an oily core coated with PAsn were prepared according to the solvent diffusion process in one step:
- an aqueous solution of polyasparagine (20 ml) was prepared in which different amounts of the polyamino acid, 5-200 mg, are dissolved;
- an oil phase consisting of an ethanol / acetone solution (0.5: 9 ml) of lecithin (30 mg) and the cationic surfactants benzalkonium chloride (4 mg) or hexadecyltrimethylammonium bromide (1.8 mg) was prepared at the one that is added 125 ⁇ of Miglyol® 812;
- Tables 28 and 29 show the values obtained from the parameters cited as a function of the amount of PAsn in the aqueous solution of step a) using benzalkonium chloride or hexadecyltrimethylammonium bromide, respectively.
- Nanocapsules consisting of an oily core coated with PAsn were prepared according to the sonication procedure:
- step ii) the solution obtained in step i) was added over 2 ml of water and sonic for 30 seconds;
- step iv) the organic solvents were evaporated to constant volume to form a cationic nanoemulsion; and v) the cationic nanoemulsion obtained in step iv) was coated by an incubation process with an aqueous solution (1 ml) composed of different amounts of polyasparagine, in a 4: 1 ratio (nanoemulsion: PAsn solution), the coating being produced immediately, regardless of temperature.
- Nanocapsules consisting of an oily core coated with polyasparagine were prepared according to the homogenization procedure:
- step ii) the solution obtained in step i) was added over 2 ml of water and homogenized at 16,000 rpm for 5 minutes and then at 19,000 rpm for another 5 minutes;
- the emulsion obtained was diluted with water (1: 10 dilution) and homogenized for 3 minutes at 22,000 rpm;
- step iv) the nanoemulsion obtained in step iv) was coated by an incubation process with an aqueous solution (1 ml) composed of different amounts of PAsn, in a 4: 1 ratio (nanoemulsion: PAsn solution), occurring immediately the coating, regardless of temperature.
- PAsn nanocapsules were prepared, with an oily core composed of lecithin, Miglyol® 812 and the cationic surfactants benzalkonium chloride (4 mg) or hexadecyltrimethyl ammonium bromide (1.8 mg).
- a lipophilic drug, docetaxel, an antitumor agent practically insoluble in water was incorporated.
- the manufacturing process corresponds to the procedure previously described in Example 1 1.1., With a slight modification, a small aliquot of a solution of the active ingredient in ethanol (1-100 mg / ml) is incorporated into the oil phase.
- the system is rotated to a constant volume and incubated with a solution of PAsn forming the nanocapsules encapsulating docetaxel with weight ratios of docetaxel / nanocapsules of PAsn of up to 30%.
- the encapsulation efficiency was determined (by evaluating the free drug by high performance liquid chromatography, obtaining an encapsulation efficiency of -75%.
- the parameters mean particle diameter, polydispersion index and zeta potential were also measured (Table 31).
- Polyaparagine nanocapsules an oily core composed of lecithin, Miglyol® 812 and benzalkonium chloride (4 mg) or hexadecyltrimethylammonium bromide (4 mg) were prepared according to the procedure previously described. Particle size measurements were made over a long period of time, in order to obtain information about the evolution of the system size over time. The effect of storage temperature (4 and 37 ° C) on the stability of the nanocapsules was also evaluated. The results presented in Figures 10a and 10b show the limited variability in the size of PAsn nanocapsules with benzalkonium chloride and hexadecyltrimethylammonium bromide respectively, during storage.
- Example 15 Example 15
- Polyaparagine nanocapsules, an oily core composed of lecithin, Miglyol® 812 and the cationic hexadecyltrimethiamonium bromide surfactant (1.8 mg) were prepared according to the procedure previously described.
- the effect of the trehalose cryoprotective agent during the lyophilization process of PAsn nanocapsules and in the subsequent recovery of particle size after resuspension was evaluated. testing two concentrations of cryoprotectant, 5 and 10% w / v.
- the influence of the concentration of nanocapsules (0.25, 0.5 and 1% w / v) on the suspension to be lyophilized was evaluated.
- the results in Table 32 show the particle size of lyophilized PAsn nanocapsules after resuspension.
- PAsn nanocapsules encapsulating docetaxel were prepared using hexadecyltrimethylammonium bromide (1.8 mg) according to the procedure described in example 12.
- the results shown in Figure 1 1 show the greater capacity to inhibit the proliferation of the nanocapsules encapsulating docetaxel compared to the free molecule when the systems are contacted for 2 and 48 hours with cancer cells
- the IC50 values were calculated using the Graph Pad Prism 2.1 program (Graph Pad Software). Thus, docetaxel solution presented IC50 values.
- Nanocapsules consisting of a polyglutamic-polyethylene glycol (PGA-PEG) shell were prepared in the form of 35,000 Da molecular weight sodium salt, with a 60% peguylation percentage and a PEG chain size of 20,000 Da; an oily core composed of lecithin, Miglyol® 812 and hexadecyltrimethylammonium bromide, of medium size 100 nm, according to the one-stage solvent diffusion process.
- PGA-PEG polyglutamic-polyethylene glycol
- nanocapsules consisting of a polyglutamic-polyethylene glycol (PGA-PEG) shell in the form of 35,000 Da sodium salt were prepared, with a 60% peguylation percentage and a PEG chain size of 20,000 Da; poloxamer 188 and an oily core composed of lecithin, Miglyol® 812 and benzalkonium chloride, medium size 200 nm, according to the same procedure.
- the size of the nanocapsules could be modulated until these sizes were reached, suitably modifying the amount of components and the method of adding the organic phase to the aqueous phase.
- the nanocapsules were labeled with the lipophilic fluorescent marker DiD ( ⁇ , ⁇ -dioctadecyl-3,3,3 ', 3'-tetramethylindodicarbocyanine perchlorate).
- DiD ⁇ , ⁇ -dioctadecyl-3,3,3 ', 3'-tetramethylindodicarbocyanine perchlorate.
- the two 100 and 200 nm nanocapsule formulations were isolated and diluted in a 10% trehalose solution in water and administered subcutaneously (in the interscapular zone) and intravenously (in the tail vein) to SCID mice healthy in order to evaluate its biodistribution, with special attention to its accumulation in lymphatic tissues.
- the injection volume was 100 ⁇ and the concentration of 100 and 200 nm nanocapsules was 12 mg / ml and 13.6 mg / ml, respectively.
- Figures 12a, 12b, and 12c show fluorescence levels (expressed in photons / sec / cm 2 / sr) in different organs and tissues after administration of 100 nm polyglutamic-polyethylene glycol nanocapsules, after different periods of time: (a) 6 hours, (b) 24 hours, (c) 48 hours; (ES administration subcutaneously, ülUJ administration intravenously).
- Figures 13a, 13b and 13c show fluorescence levels (expressed in photons / sec / cm 2 / sr) in different organs and tissues after administration of 200 nm polyglutamic-polyethylene glycol nanocapsules, after different time periods: (a) 6 hours, (b) 24 hours, (c) 48 hours; ( ⁇ administration subcutaneously, U üJ administration intravenously).
- the results show the high lymphatic accumulation of the fluorescence associated with the nanocapsules after administration by both routes, this accumulation being more pronounced for subcutaneous administration.
- a clear vehiculization of the marker towards the lymphatic system is seen. This lymphatic accumulation is associated with a reduction of the accumulation in organs responsible for elimination such as liver and spleen.
- Nanocapsules with different polymers including PAsn, PGA or PGA-PEG were prepared by means of the technique in a step described in example 1.1 and 11.1. These systems were loaded with the DiD fluorescent marker (l, l'-dioctadecyl-3,3,3'3, '- tetramethylindodicarbocyanine perchlorate) (concentration of DiD in the nanocapsules of 100 ⁇ g / ml) prior to administration in Swiss mice (from 9-12 weeks, 20-22 g). An anionic nanoemulsion charged with the same marker and at the same concentration was used as the control formulation. Likewise, a control experiment was performed to determine the residual fluorescence of the plasma, from blood samples from mice to which 150 ⁇ of physiological saline was administered.
- DiD fluorescent marker l, l'-dioctadecyl-3,3,3'3, '- tetramethylindodicarbocyanine perchlorate
- the fluorescent formulations, nanocapsules and nanoemulsion, as well as the physiological serum control sample were administered by IV tail injection of mice in a volume of 150 ⁇ .
- blood samples were taken, in triplicate, by cardiac puncture.
- the samples were centrifuged for 10 min at 2000g in a Vacutainer tube (SST II Advance, 5 ml, Becton Dickinson France SAS, France).
- Fluorescence is expressed in fluorescence units (FU) and is calculated by the following equation:
- Figure 14 shows the percentage of injected fluorescence dose (concentration of DiD in mg / kg of the total weight of the animal at each time in relation to the concentration at zero time) that remains in plasma after different periods of time after injection intravenous in Swiss mice. 100% fluorescence corresponds to zero time fluorescence.
- the results that appear in Figure 14 show the differences in the rate of plasma elimination of the different formulations evaluated.
- Lz being the slope corresponding to the linearization of each phase of the plasma levels-time curve. Lz was determined by linear regression using predefined intervals (for distribution half - life [0-1 h] and for t ⁇ to removal [1-24 h] respectively). For the determination of the area under the curve (AUC) a trapezoidal model was used during the experimental time (AUC [0-24 h]) without extrapolation as well as for the AUMC. The average residence time in the organism (MRT) was calculated from 0 to 24 h, according to the equation:
- Table 1 shows the values corresponding to the parameters: the average distribution life time (alpha phase) (ti / 2 a, hours), calculated from 0 to 1 hours, the average elimination life time (beta phase) ( tm ⁇ , hours), calculated from 1 to 24 hours, the average residence time (MRT, hours), calculated from 0 to 24 hours and area under the plasma levels / time curve (AUC, hours), calculated from 0 to 24 hours.
- the results obtained for these parameters show the differences in the plasma elimination kinetics of the different formulations.
- the overall conclusion of these results is the prolonged permanence of all the nanocapsules in plasma, a very favorable behavior when it comes to vehicularizing active ingredients towards tumor zones.
- Table 1 Pharmacokinetic parameters of the nanocapsules of PGA, PGA-PEG, PAsn and the nanoemulsion used as control after administration I.V. in mice
- mice When the tumor reached a size of 200 mm, the mice were distributed in 4 groups to which different treatments were administered (the PAG-PEG nanocapsules, the PAsn nanocapsules, the control nanoemulsion and the commercial Taxotere® formulation).
- the injected formulation volume was a maximum of 150
- Tumor size was measured twice a week for a period of 24 days.
- Figure 15a shows the evolution in the increase of the tumor volume (difference between the size at each time and the initial size) of the animals treated with the nanocapsules loaded with drug, as well as with Taxotere® and with the control of saline serum. The results indicate first, that docetaxel retains its antitumor activity in vivo when encapsulated.
- the nanocapsule formulations were as effective as the commercial formulation, both formulations being effective in reducing the rate of tumor growth.
- Figure 15b shows the increase in tumor volume after 18 and 21 days in relation to size at zero time. It can be seen that the differences in tumor size of treated and untreated animals (serum were administered) were significant for both times.
- Figure 16 shows the percentage of mice that survive after different periods of time and after being subjected to different treatments, according to the Kaplan-Meier method. The results show a much higher survival in the case of mice treated with nanocapsule formulations (between 60-80% survival) than with Taxotere® (30% survival). This reduction in the toxicity of the drug formulated in the form of nanocapsules has to be attributed to a greater selectivity of the treatment, which is in line with the prolonged circulation time of the nanocapsules in plasma. The previous results were also analyzed in terms of mean and median survival after tumor implantation.
- Table 2 shows the survival time of the animals expressed as range (difference between the longest and shortest time), the arithmetic mean and stardard deviation (SD) of the mean survival time and the median. Also, table 2 shows the percentage of the increase in survival (% IST) calculated from the mean or median values. For example, in the case of the mean, the calculation would be done according to the equation:
- Table 2 Average survival time of animals treated with the different nanocapsule formulations loaded with docetaxel, compared to those obtained after the administration of Taxotere ® and control of saline.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nanotechnology (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Biomedical Technology (AREA)
- Optics & Photonics (AREA)
- Medical Informatics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Inorganic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP12734760.7A EP2664324B1 (en) | 2011-01-10 | 2012-01-09 | Nanocapsules with a polymer shell |
BR112013017750A BR112013017750A8 (pt) | 2011-01-10 | 2012-01-09 | nanocápsulas com revestimento polimérico |
CN201280012254.4A CN103596558A (zh) | 2011-01-10 | 2012-01-09 | 聚合物壳纳米微胶囊 |
US13/979,092 US9415019B2 (en) | 2011-01-10 | 2012-01-09 | Nanocapsules with a polymer shell |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ES201130015A ES2385995B2 (es) | 2011-01-10 | 2011-01-10 | Nanocápsulas con cubierta polimérica |
ESP201130015 | 2011-01-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2012095543A1 true WO2012095543A1 (es) | 2012-07-19 |
Family
ID=46506792
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/ES2012/000008 WO2012095543A1 (es) | 2011-01-10 | 2012-01-09 | Nanocápsulas con cubierta polimérica |
Country Status (6)
Country | Link |
---|---|
US (1) | US9415019B2 (es) |
EP (1) | EP2664324B1 (es) |
CN (1) | CN103596558A (es) |
BR (1) | BR112013017750A8 (es) |
ES (1) | ES2385995B2 (es) |
WO (1) | WO2012095543A1 (es) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103483353A (zh) * | 2012-06-13 | 2014-01-01 | 上海现代药物制剂工程研究中心有限公司 | 二硫杂环戊烯并吡咯酮化合物的纳米粒及制备方法 |
CN105283176A (zh) * | 2012-12-17 | 2016-01-27 | 圣地亚哥-德孔波斯特拉大学 | 鱼精蛋白纳米胶囊 |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2013527157A (ja) | 2010-04-15 | 2013-06-27 | ワシントン・ユニバーシティ | プロドラッグ組成物、プロドラッグナノ粒子およびその使用方法 |
AU2016343840A1 (en) * | 2015-10-30 | 2018-06-07 | The Johns Hopkins University | Mucus penetrating particles with high molecular weight and dense coatings |
ES2664584B2 (es) | 2016-09-19 | 2018-12-13 | Universidade De Santiago De Compostela | Nanoparticulas con interiores protegidos, y métodos de uso de las mismas |
WO2018064393A1 (en) * | 2016-09-30 | 2018-04-05 | President And Fellows Of Harvard College | Materials including polymeric fibers incorporating microcapsules or nanocapsules including an essential oil |
US10918685B2 (en) * | 2017-01-05 | 2021-02-16 | Ravi Ramamoorthy Iyer | Herbal topical composition for muscle and joint health, recovery from exertion, and for pain management |
WO2018169960A1 (en) * | 2017-03-17 | 2018-09-20 | The Johns Hopkins University | Nanoparticle formulations for enhanced drug delivery to the bladder |
ES2711669A1 (es) * | 2017-11-02 | 2019-05-06 | Univ Santiago Compostela | Sistemas de liberacion de farmacos de acido polisialico y metodos |
WO2020255114A1 (en) * | 2019-06-20 | 2020-12-24 | Lyotropic Delivery Systems Ltd. | Polymeric soft films embedded with nanodomains and/or a bioactive and methods of producing same |
CN111544643B (zh) * | 2020-04-23 | 2022-06-07 | 海南芬森医疗器械有限公司 | γ-聚谷氨酸皮肤屏障修复敷料及其制备方法 |
US11696888B2 (en) | 2020-05-27 | 2023-07-11 | Mary Kay Inc. | Topical compositions and methods |
CN115152739A (zh) * | 2021-04-01 | 2022-10-11 | 中国科学院理化技术研究所 | 一种加载海藻糖的聚合物纳米颗粒及其制备方法与应用 |
CN115193263B (zh) * | 2022-08-03 | 2023-04-18 | 广西大学 | 一种旋转膜过滤净化装置及其应用、净化山茶油的方法 |
Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996006622A1 (en) | 1991-07-03 | 1996-03-07 | Hyal Pharmaceutical Corporation | Hyaluronic acid and derivatives for modulation of cellular activity |
US6326511B1 (en) | 1997-08-18 | 2001-12-04 | Lajos Kossuth University | Polymeric product |
US6383478B1 (en) | 1999-04-22 | 2002-05-07 | Vanderbilt University | Polymeric encapsulation system promoting angiogenesis |
US20030166602A1 (en) | 1999-12-03 | 2003-09-04 | Szoka Francis C. | Targeted drug delivery with a CD44 receptor ligand |
US20030170201A1 (en) | 2000-09-26 | 2003-09-11 | Kazunori Kataoka | Polymeric micelle containing cisplatin enclosed therein and use thereof |
WO2004112758A1 (es) | 2003-06-20 | 2004-12-29 | Advanced In Vitro Cell Technologies, S.L. | Nanopartículas de ácido hialurónico |
US20050238678A1 (en) | 2004-03-05 | 2005-10-27 | Janos Borbely | Hydrogels from biopolymers |
US20060246096A1 (en) | 2003-12-29 | 2006-11-02 | University of Debrecen, Department of Colloid and Environmental Chemistry | Nanoparticles from biopolymers |
US20070224277A1 (en) | 2005-12-23 | 2007-09-27 | Janos Borbely | Hyaluronic acid-based cross-linked nanoparticles |
WO2009087678A2 (en) * | 2007-12-24 | 2009-07-16 | Sun Pharma Advanced Research Company Limited | Nanodispersion |
BRPI0803473A2 (pt) * | 2008-09-18 | 2010-06-15 | Fundacao De Amparo A Pesquisa | nanopartìcula transportadora de fármacos, processo de preparo e composição farmacêutica compreendendo a mesma e método para entrega de fármacos |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4670185A (en) * | 1982-07-19 | 1987-06-02 | Lion Corporation | Aqueous vesicle dispersion having surface charge |
IL101241A (en) * | 1992-03-16 | 1997-11-20 | Yissum Res Dev Co | Pharmaceutical or cosmetic composition comprising stabilized oil-in-water type emulsion as carrier |
JP2811036B2 (ja) * | 1992-05-26 | 1998-10-15 | 参天製薬株式会社 | ビタミンe点眼剤 |
DE4244122C1 (de) * | 1992-12-24 | 1994-06-01 | Sanol Arznei Schwarz Gmbh | Lyophilisierte, wirkstoffhaltige Emulsion zur intravenösen Applikation |
US6365706B1 (en) * | 2000-06-21 | 2002-04-02 | Mississippi Chemical Corporation | Process for production of polyasparagine and the high nitrogen content polymer formed thereby |
US20040047891A1 (en) * | 2001-02-26 | 2004-03-11 | Sabina Glozman | Systems devices and methods for intrabody targeted delivery and reloading of therapeutic agents |
WO2002087563A2 (en) * | 2001-05-01 | 2002-11-07 | Angiotech Pharmaceuticals Inc. | Compositions comprising an anti-microtubule agent and a polypeptide or a polysaccharide and the use thereof for the preparation of a medicament for the treatment of inflammatory conditions |
KR100874847B1 (ko) * | 2001-06-01 | 2008-12-19 | 아스텔라스 파마 유럽 비.브이. | 지질-폴리머-접합체 |
US20050196370A1 (en) * | 2003-03-18 | 2005-09-08 | Zhi-Jian Yu | Stable ophthalmic oil-in-water emulsions with sodium hyaluronate for alleviating dry eye |
ES2232287B1 (es) * | 2003-07-04 | 2006-11-01 | Advanced In Vitro Cell Technologies, S.L. | Nanoparticulas de derivados polioxietilenados. |
US7879885B2 (en) * | 2004-03-24 | 2011-02-01 | Array Biopharma, Inc. | Thioalkeneamides as transketolase inhibitors |
WO2006014706A2 (en) * | 2004-07-21 | 2006-02-09 | Serenex, Inc. | Methotrexate derivatives useful for treating cancer and arthritis |
US8114842B1 (en) * | 2004-10-05 | 2012-02-14 | Gp Medical, Inc. | Nanoparticles for drug delivery |
US7541028B2 (en) * | 2005-01-04 | 2009-06-02 | Gp Medical, Inc. | Nanoparticles for monoclonal antibody delivery |
US20070099856A1 (en) * | 2005-05-13 | 2007-05-03 | Gumerlock Paul H | Combined treatment with docetaxel and an epidermal growth factor receptor kinase inhibitor using an intermittent dosing regimen |
CN101062017B (zh) * | 2006-04-26 | 2010-05-12 | 科妍生物科技股份有限公司 | 一种透明质酸及其制备方法 |
-
2011
- 2011-01-10 ES ES201130015A patent/ES2385995B2/es active Active
-
2012
- 2012-01-09 WO PCT/ES2012/000008 patent/WO2012095543A1/es active Application Filing
- 2012-01-09 EP EP12734760.7A patent/EP2664324B1/en active Active
- 2012-01-09 CN CN201280012254.4A patent/CN103596558A/zh active Pending
- 2012-01-09 US US13/979,092 patent/US9415019B2/en active Active
- 2012-01-09 BR BR112013017750A patent/BR112013017750A8/pt not_active Application Discontinuation
Patent Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996006622A1 (en) | 1991-07-03 | 1996-03-07 | Hyal Pharmaceutical Corporation | Hyaluronic acid and derivatives for modulation of cellular activity |
US6326511B1 (en) | 1997-08-18 | 2001-12-04 | Lajos Kossuth University | Polymeric product |
US6383478B1 (en) | 1999-04-22 | 2002-05-07 | Vanderbilt University | Polymeric encapsulation system promoting angiogenesis |
US20030166602A1 (en) | 1999-12-03 | 2003-09-04 | Szoka Francis C. | Targeted drug delivery with a CD44 receptor ligand |
US20030170201A1 (en) | 2000-09-26 | 2003-09-11 | Kazunori Kataoka | Polymeric micelle containing cisplatin enclosed therein and use thereof |
WO2004112758A1 (es) | 2003-06-20 | 2004-12-29 | Advanced In Vitro Cell Technologies, S.L. | Nanopartículas de ácido hialurónico |
US20060246096A1 (en) | 2003-12-29 | 2006-11-02 | University of Debrecen, Department of Colloid and Environmental Chemistry | Nanoparticles from biopolymers |
US20050238678A1 (en) | 2004-03-05 | 2005-10-27 | Janos Borbely | Hydrogels from biopolymers |
US20070224277A1 (en) | 2005-12-23 | 2007-09-27 | Janos Borbely | Hyaluronic acid-based cross-linked nanoparticles |
WO2009087678A2 (en) * | 2007-12-24 | 2009-07-16 | Sun Pharma Advanced Research Company Limited | Nanodispersion |
BRPI0803473A2 (pt) * | 2008-09-18 | 2010-06-15 | Fundacao De Amparo A Pesquisa | nanopartìcula transportadora de fármacos, processo de preparo e composição farmacêutica compreendendo a mesma e método para entrega de fármacos |
Non-Patent Citations (18)
Title |
---|
BARBAULTFOUCHER ET AL., JOURNAL OF CONTROLLED RELEASE, vol. 83, 2002, pages 365 - 375 |
BLANCO ET AL., CLIN. EXP RHEUMATOL., vol. 22, no. 3, 2004, pages 307 - 12 |
BUESCHER; MARGARITIS, CRIT REVBIOTECH, 2007 |
CABRERA ET AL., J. CONTROL. RELEASE, vol. 101, 2005, pages 223 - 232 |
DEKIE J., CONTROL. RELEASE, vol. 65, 2000, pages 187 - 202 |
DUBRUEL ET AL., BIOMACROMOLECULES, vol. 4, 2003, pages 1168 - 1176 |
GREENE; WUTS: "Protective Groups in Organic Synthesis", 1999, JOHN WILEY & SONS, INC. |
HOSTE ET AL., J. CONTROL. RELEASE, vol. 64, 2000, pages 53 - 61 |
KIM ET AL., J. GENE MED, vol. 11, 2009, pages 791 |
LUO; PRESTWICH, BIOCONJUGATE CHEM, vol. 10, 1999, pages 755 - 763 |
NISHIDA ET AL., EXP. EYE RES, vol. 53, 1991, pages 753 - 758 |
NISHIYAMA ET AL., CANCER RESEARCH, vol. 63, 2003, pages 8977 - 8983 |
PREGO ET AL., J. NANOSCI. NANOTECHNOL., vol. 6, 2006, pages 1 |
SAND ET AL., ACTA OPHTHALMOL., vol. 67, 1989, pages 181 - 183 |
TADROS ET AL., ADV. COLLOID INTERFACE SCI, vol. 109, 2004, pages 303 |
VERONESE ET AL., DDT, vol. 10, no. 21, 2005, pages 1451 - 1458 |
YENICE ET AL., EXPERIMENTAL EYE RESEARCH, vol. 87, no. 3, 2008, pages 162 - 7 |
YENICE I. ET AL.: "Hyaluronic acid coated poly-epsilon-caprolactone nanospheres deliver high concentrations of cyclosporine A into the cornea", EXPERIMENTAL EYE RESEARCH, vol. 87, 2008, pages 162 - 167, XP025348994 * |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103483353A (zh) * | 2012-06-13 | 2014-01-01 | 上海现代药物制剂工程研究中心有限公司 | 二硫杂环戊烯并吡咯酮化合物的纳米粒及制备方法 |
CN103483353B (zh) * | 2012-06-13 | 2016-02-24 | 上海现代药物制剂工程研究中心有限公司 | 二硫杂环戊烯并吡咯酮化合物的纳米粒及制备方法 |
CN105283176A (zh) * | 2012-12-17 | 2016-01-27 | 圣地亚哥-德孔波斯特拉大学 | 鱼精蛋白纳米胶囊 |
JP2016503780A (ja) * | 2012-12-17 | 2016-02-08 | ウニベルシダッデ デ サンティアゴ デ コンポステーラ | プロタミンナノカプセル |
US20160038433A1 (en) * | 2012-12-17 | 2016-02-11 | Universidade De Santiago De Compostela | Nanocapsules of protamine |
US9642816B2 (en) * | 2012-12-17 | 2017-05-09 | Universidade De Santiago De Compostela | Nanocapsules of protamine |
Also Published As
Publication number | Publication date |
---|---|
EP2664324A4 (en) | 2015-05-27 |
ES2385995B2 (es) | 2013-05-21 |
BR112013017750A8 (pt) | 2018-03-06 |
CN103596558A (zh) | 2014-02-19 |
ES2385995A1 (es) | 2012-08-06 |
EP2664324A1 (en) | 2013-11-20 |
BR112013017750A2 (pt) | 2016-10-11 |
EP2664324B1 (en) | 2019-09-25 |
US9415019B2 (en) | 2016-08-16 |
US20140023703A1 (en) | 2014-01-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2385995B2 (es) | Nanocápsulas con cubierta polimérica | |
Majumder et al. | Nanocarrier-based systems for targeted and site specific therapeutic delivery | |
Jia et al. | A novel dexamethasone-loaded liposome alleviates rheumatoid arthritis in rats | |
Mo et al. | PEGylated hyaluronic acid-coated liposome for enhanced in vivo efficacy of sorafenib via active tumor cell targeting and prolonged systemic exposure | |
Wang et al. | RGD peptide conjugated liposomal drug delivery system for enhance therapeutic efficacy in treating bone metastasis from prostate cancer | |
ES2671047T3 (es) | Encapsulado de fotosensibilizadores en nanoemulsiones | |
ES2923929T3 (es) | Formulación liposomal para uso en el tratamiento del cáncer | |
KR20200130704A (ko) | 약물 전달 시스템 | |
Yoon et al. | Docetaxel-loaded RIPL peptide (IPLVVPLRRRRRRRRC)-conjugated liposomes: drug release, cytotoxicity, and antitumor efficacy | |
US10632081B2 (en) | Intralymphatic delivery of hyaluronan nanoparticle for cancer metastasis | |
ES2951598T3 (es) | Composición farmacéutica que combina al menos dos nanopartículas distintas y un compuesto farmacéutico, preparación y usos de los mismos | |
Marzban et al. | Optimizing the therapeutic efficacy of cisplatin PEGylated liposomes via incorporation of different DPPG ratios: In vitro and in vivo studies | |
Wei et al. | Janus nanogels of PEGylated Taxol and PLGA–PEG–PLGA copolymer for cancer therapy | |
KR20110056042A (ko) | 종양세포 표적지향을 위한 나노 입자 및 이의 제조방법 | |
AU2006321796A1 (en) | Liposomal compositions | |
US20180207104A1 (en) | Improved nanoparticle delivery systems | |
ES2481940B1 (es) | Nanocápsulas de protamina | |
WO2021057007A1 (zh) | 一种雷帕霉素纳米缓释剂及其制备方法 | |
Ao et al. | Low density lipoprotein modified silica nanoparticles loaded with docetaxel and thalidomide for effective chemotherapy of liver cancer | |
ES2347119B2 (es) | Nanocapsulas de poliarginina. | |
KR20100075490A (ko) | 신규 탁소이드-기재 조성물 | |
WO2009121997A2 (es) | Nanopartículas pegiladas que comprenden una molécula biológicamente activa y sus aplicaciones | |
Tang et al. | Construction and evaluation of hyaluronic acid-based copolymers as a targeted chemotherapy drug carrier for cancer therapy | |
WO2016066864A1 (es) | Nanopartículas para la liberación controlada de ingredientes activos | |
Karimi et al. | Prolonged local delivery of doxorubicin to cancer cells using lipid liquid crystalline system |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 12734760 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2012734760 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13979092 Country of ref document: US |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112013017750 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 112013017750 Country of ref document: BR Kind code of ref document: A2 Effective date: 20130710 |